09. 11(Fri)
09. 11(Fri)
08:30~10:00 Room 2
New Frontiers in Lipid Lowering: Beyond Statins (New Drugs 1)
-
Bempedoic acid: LDL-C lowering beyond statins - evidence and clinical role
Che Wan Lim Catholic Kwandong University, Republic of Korea 08:30~08:50 -
Optimizing non-statin therapy: PCSK9 inhibitors and inclisiran
TBD (Name) TBD (Affiliation, Country) 08:50~09:10 -
Emerging Lp(a)-lowering therapies: siRNA, ASO, and beyond
Yu-Chen Wang Asia University, Taiwan 09:10~09:30 - Panel Discussion 09:30~10:00
09. 11(Fri)
16:10~17:40 Room 2
Next-generation Lipid-lowering Therapies: CETP, APOC3, and ANGPTL3 Inhibition (New Drugs 2)
-
CETP inhibition revisited: obicetrapib for LDL-C reduction and ASCVD risk management
Mariko Harada-Shiba Osaka Medical and Pharmaceutical University, Japan 16:10~16:30 -
APOC3 inhibition: targeting triglyceride-rich lipoproteins and residual risk
Jin Wi Gachon University, Republic of Korea 16:30~16:50 -
ANGPTL3 inhibition: expanding therapeutic opportunities beyond LDL-C
Hye Moon Chung Kyung Hee University, Republic of Korea 16:50~17:10 - Panel Discussion 17:10~17:40
